Last reviewed · How we verify
Alpha-1 15%
At a glance
| Generic name | Alpha-1 15% |
|---|---|
| Sponsor | Grifols Therapeutics LLC |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency (PHASE1, PHASE2)
- A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (PHASE2)
- Prazosin and Cerebrospinal Fluid (CSF) Biomarkers in Mild Traumatic Brain Injury (mTBI) (PHASE4)
- Aralast NP in Islet Transplant (PHASE1, PHASE2)
- Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer (PHASE2)
- Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency (PHASE1, PHASE2)
- Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency (PHASE2)
- Role of Acetylcholine in Blood Flow Regulation in Healthy Adults: Effects of Age and Exercise Training (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alpha-1 15% CI brief — competitive landscape report
- Alpha-1 15% updates RSS · CI watch RSS
- Grifols Therapeutics LLC portfolio CI